In quest of a new therapeutic approach in COVID-19: the endocannabinoid system

References

• Almogi-Hazan O, Or R. 2020. Cannabis, the endocannabinoid system and immunity-the journey from the bedside to the bench and back. IJMS. 21(12):4448.
   Web of Science ®Google Scholar
• Anil SM, Shalev N, Vinayaka AC, Nadarajan S, Namdar D, Belausov E, Shoval I, Mani KA, Mechrez G, Koltai H. 2021. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep. 11(1):1462.
   PubMed Web of Science ®Google Scholar
• Apostu D, Lucaciu O, Mester A, Benea H, Oltean-Dan D, Onisor F, Baciut M, Bran S. 2019. Cannabinoids and bone regeneration. Drug Metab Rev. 51(1):65–75.
   PubMed Web of Science ®Google Scholar
• Bähr I, Spielmann J, Quandt D, Kielstein H. 2020. Obesity-associated alterations of natural killer cells and immunosurveillance of cancer. Front Immunol. 11:245.
   PubMed Web of Science ®Google Scholar
• Beji C, Loucif H, Telittchenko R, Olagnier D, Dagenais-Lussier X, van Grevenynghe J. 2020. Cannabinoid-induced immunomodulation during viral infections: a focus on mitochondria. Viruses. 12(8):875.
   PubMed Web of Science ®Google Scholar
• Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 4(6):1011–1033.
   PubMed Web of Science ®Google Scholar
• Bosch BJ, van der Zee R, De Haan CA, Rottier PJ. 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 77(16):8801–8811.
   PubMed Web of Science ®Google Scholar
• Byrareddy SN, Mohan M. 2020. SARS-CoV2 induced respiratory distress: can cannabinoids be added to anti-viral therapies to reduce lung inflammation? Brain Behav Immun. 87:120–121.
   PubMed Web of Science ®Google Scholar
• Cabral GA, Griffin-Thomas L. 2009. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med. 11 :e3.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan China: a descriptive study. Lancet. 395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Costiniuk CT, Jenabian MA. 2020. Acute inflammation and pathogenesis of SARS-CoV-2 infection: cannabidiol as a potential anti-inflammatory treatment? Cytokine Growth Factor Rev. 53:63–65.
   PubMed Web of Science ®Google Scholar
• Eisenstein TK, Meissler JJ. 2015. Effects of cannabinoids on T-cell function and resistance to infection. J Neuroimmune Pharmacol. 10(2):204–216.
   PubMed Web of Science ®Google Scholar
• Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, Sarnelli G. 2020. The potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol. 177(21):4967–4970.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui D, China Medical Treatment Expert Group for Covid-19, et al. 2020. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Guillot A, Hamdaoui N, Bizy A, Zoltani K, Souktani R, Zafrani ES, Mallat A, Lotersztajn S, Lafdil F. 2014. Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology. 59(1):296–306.
   PubMed Web of Science ®Google Scholar
• Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. 2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 7(1):11.
   PubMed Web of Science ®Google Scholar
• Gyurova IE, Ali A, Waggoner SN. 2020. Natural killer cell regulation of B cell responses in the context of viral infection. Viral Immunol. 33(4):334–341.
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. 2004. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 203(2):631–637.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet (London England). 395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Hui DS, Lee N, Chan PK, Beigel JH. 2018. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res. 150:202–216.
   PubMed Web of Science ®Google Scholar
• Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. 2020. Virology epidemiology pathogenesis and control of COVID-19. Viruses. 12(4):372.
   PubMed Web of Science ®Google Scholar
• Khodadadi H, Salles ÉL, Jarrahi A, Chibane F, Costigliola V, Yu JC, Vaibhav K, Hess DC, Dhandapani KM, Baban B. 2020. Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA. Cannabis Cannabinoid Res. 5(3):197–201.
   PubMedGoogle Scholar
• Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, Vogel Z. 2013. Cannabinoids decrease the th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol. 8(5):1265–1276.
   PubMed Web of Science ®Google Scholar
• Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung K, Lau E, Wong JY, et al. 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 382(13):1199–1207.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426(6965):450–454.
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Chen K, Li J, Wang X, Wang F, et al. 2020. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. MedRxiv. DOI:https://doi.org/10.1101/2020.02.23.20026690.
   Google Scholar
• Lu HC, Mackie K. 2016. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 79(7):516–525.
   PubMed Web of Science ®Google Scholar
• Lu T, Newton C, Perkins I, Friedman H, Klein TW. 2006. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther. 319(1):269–276.
   PubMed Web of Science ®Google Scholar
• Lucaciu O, Tarczali D, Petrescu N. 2020. Oral Healthcare during the COVID-19 pandemic. J Dent Sci. 15:399–402.
   PubMed Web of Science ®Google Scholar
• Mamber SW, Krakowka S, Osborn J, Saberski L, Rhodes RG, Dahlberg AE, Pond-Tor S, Fitzgerald K, Wright N, Beseme S, et al. 2020. Can unconventional immunomodulatory agents help alleviate COVID-19 symptoms and severity? mSphere. 5(3):E00288–20.
   PubMed Web of Science ®Google Scholar
• Mohammed A, Alghetaa HK, Zhou J, Chatterjee S, Nagarkatti P, Nagarkatti M. 2020. Protective effects of Δ9 -tetrahydrocannabinol against enterotoxin-induced acute respiratory distress syndrome are mediated by modulation of microbiota. Br J Pharmacol. 177(22):5078–5095.
   PubMed Web of Science ®Google Scholar
• Mormina ME, Thakur S, Molleman A, Whelan CJ, Baydoun AR. 2006. Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur J Pharmacol. 540(1–3):183–190.
   PubMed Web of Science ®Google Scholar
• Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. 2009. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 1(7):1333–1349.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. 2017. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington (DC): National Academies Press (US). Challenges and barriers in conducting cannabis research. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425757/.
   Google Scholar
• Nichols JM, Kaplan B. 2020. Immune responses regulated by cannabidiol. Cannabis Cannabinoid Res. 5(1):12–31.
   PubMedGoogle Scholar
• Nüssing S, Sant S, Koutsakos M, Subbarao K, Nguyen T, Kedzierska K. 2018. Innate and adaptive T cells in influenza disease. Front Med. 12(1):34–47.
   PubMed Web of Science ®Google Scholar
• Onaivi ES, Sharma V. 2020. Cannabis for COVID-19: can cannabinoids quell the cytokine storm? Future Sci Oa. 6(8):FSO625
   PubMed Web of Science ®Google Scholar
• O'Sullivan SE, Kendall DA. 2010. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology. 215(8):611–616.
   PubMed Web of Science ®Google Scholar
• Pacher P, Bátkai S, Kunos G. 2006. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 58(3):389–462.
   PubMed Web of Science ®Google Scholar
• Paloczi J, Varga ZV, Hasko G, Pacher P. 2018. Neuroprotection in oxidative stress-related neurodegenerative diseases: role of endocannabinoid system modulation. Antioxid Redox Signal. 29(1):75–108.
   PubMed Web of Science ®Google Scholar
• Park WB, Kwon NJ, Choi SJ, Kang CK, Choe PG, Kim JY, Yun J, Lee GW, Seong MW, Kim NJ, Seo JS, et al. 2020. Virus isolation from the first patient with SARS-CoV-2 in Korea. J Korean Med Sci. 35(7):e84.
   PubMed Web of Science ®Google Scholar
• Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, HKU/UCH SARS Study Group, et al. 2003. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 361(9371):1767–1772.
   PubMed Web of Science ®Google Scholar
• Petrescu NB, Jurj A, Sorițău O, Lucaciu OP, Dirzu N, Raduly L, Berindan-Neagoe I, Cenariu M, Boșca BA, Campian RS, et al. 2020. Cannabidiol and vitamin D3 impact on osteogenic differentiation of human dental mesenchymal stem cells. Medicina (Kaunas Lithuania). 56(11):607.
   PubMed Web of Science ®Google Scholar
• Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, et al. 2017. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther. 175:133–150.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, et al. 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 71(15):762–768.
   PubMed Web of Science ®Google Scholar
• Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. 2020. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens (Basel Switzerland). 9(3):231.
   PubMed Web of Science ®Google Scholar
• Raj V, Park JG, Cho KH, Choi P, Kim T, Ham J, Lee J. 2021. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. Int J Biol Macromol. 168:474–485.
   PubMed Web of Science ®Google Scholar
• Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F. 2020. Cannabinoid receptor type 2: a possible target in SARS-CoV-2 (CoV-19) infection? IJMS. 21(11):3809.
   Web of Science ®Google Scholar
• Sainz-Cort A, Heeroma JH. 2020. The interaction between the endocannabinoid system and the renin angiotensin system and its potential implication for COVID-19 infection. J Cannabis Res. 2(1):23.
   PubMedGoogle Scholar
• Salles ÉL, Khodadadi H, Jarrahi A, Ahluwalia M, Paffaro VAJr, Costigliola V, Yu JC, Hess DC, Dhandapani KM, Baban B. 2020. Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome. J Cell Mol Med. 24(21):12869–12872.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Tramsen L, Rais B, Ullrich E, Lehrnbecher T. 2018. Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives. Oncotarget. 9(29):20891–20907.
   PubMedGoogle Scholar
• Simcocks AC, O’Keefe L, Hryciw DH, Mathai ML, Hutchinson DS, McAinch AJ. 2018. GPR55. In: Choi S, editor. Encyclopedia of signaling molecules. Cham: Springer.
   Google Scholar
• Song Y, Zhang M, Yin L, Wang K, Zhou Y, Zhou M, Lu Y. 2020. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents. 56(2):106080.
   PubMed Web of Science ®Google Scholar
• Tahamtan A, Tavakoli-Yaraki M, Rygiel TP, Mokhtari-Azad T, Salimi V. 2016. Effects of cannabinoids and their receptors on viral infections. J Med Virol. 88(1):1–12.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, MacAry PA, Ng L. 2020. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 20(6):363–374.
   PubMed Web of Science ®Google Scholar
• Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. 2020. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 15(5):700–704.
   PubMed Web of Science ®Google Scholar
• Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens RW, Razonable RR. 2020. Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof). Mayo Clin Proc. 95(7):1454–1466.
   PubMed Web of Science ®Google Scholar
• Wang B, Kovalchuk A, Li D, Rodriguez-Juarez R, Ilnytskyy Y, Kovalchuk I, Kovalchuk O. 2020. In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY). 12(22):22425–22444.
   PubMedGoogle Scholar
• Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, Lit LCW, Hui DSC, Chan MHM, Chung SSC, et al. 2004. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical and Experimental Immunology. 136(1):95–103.
   PubMed Web of Science ®Google Scholar
• Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. 2020. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 12(1):8.
   PubMed Web of Science ®Google Scholar
• Yang M. 2020. Cell pyroptosis A potential pathogenic mechanism of 2019-nCoV infection. SSRN. DOI:https://doi.org/10.2139/ssrn.3527420.
   Google Scholar
• Zhang B, Zhou X, Qiu Y, Song Y, Feng F, Feng J, Song Q, Jia Q, Wang J. 2020. Clinical characteristics of 82 cases of death from COVID-19. PloS One. 15(7):e0235458.
   PubMed Web of Science ®Google Scholar
• Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, Li M, Zheng W, Yi L, Chen X, et al. 2020. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outseide Hubei province China: a descriptive and modelling study. Lancet. 20(7):793–802.
   Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, Sun R, Tian Z, Xu X, Wei H. 2020. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 7(6):998–1002.
   PubMed Web of Science ®Google Scholar
• Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, et al. 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 382(12):1177–1179.
   PubMed Web of Science ®Google Scholar
• Zou X, Chen K, Zou J, Han P, Hao J, Han Z. 2020. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 14(2):185–192.
   PubMed Web of Science ®Google Scholar